Non-Invasive Embryo Screening Doesn't Boost Pregnancy Rates for Older IVF Patients, Trial Finds

Couples going through IVF later in reproductive life often face a difficult question: is there a way to pick the embryo most likely to lead to a healthy pregnancy? One technology marketed for this purpose, non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), analyzes DNA fragments shed into the fluid surrounding a developing embryo, rather than requiring a biopsy of the embryo itself. It's appealing because it avoids touching the embryo directly, but until now there hasn't been strong evidence from a large randomized trial showing whether it actually improves outcomes.

A new study published in Nature Communications set out to test that question directly, and the results complicate the case for using this technology routinely.

How the trial was designed

Researchers across 13 fertility centers in China enrolled 1,152 women between ages 35 and 42 who were undergoing single frozen-thawed blastocyst transfer and had at least two blastocysts available. Participants were randomly split into two groups. In one, embryos were chosen for transfer based on niPGT-A results. In the other, embryo selection relied on standard morphological assessment — essentially, how the embryo looks under a microscope. Neither the clinicians analyzing outcomes nor the patients knew which method had guided their embryo choice, a double-blind design meant to reduce bias in reporting results.

The main outcome tracked was the ongoing pregnancy rate, defined as a pregnancy that continued past 12 weeks. The team also looked at clinical pregnancy rates, miscarriage, live births, and outcomes for both mothers and newborns.

What the numbers showed

The headline finding is fairly simple: niPGT-A didn't produce a statistically meaningful advantage on the primary measure. Ongoing pregnancy occurred in 38.7% of the niPGT-A group compared with 36.8% of the morphology group, a gap the researchers determined wasn't statistically significant once adjustments were applied.

The pattern held for most secondary measures too. Clinical pregnancy rates were nearly identical between groups (47.6% versus 49.9%), and live birth rates showed no meaningful difference either (37.0% versus 35.5%). Miscarriage overall trended lower in the niPGT-A group but didn't reach statistical significance.

One result stood out from the rest: early miscarriage, meaning pregnancy loss before 12 weeks, was lower in the niPGT-A group — 18.0% compared with 25.2% in the morphology group, a difference the researchers did consider statistically significant. This hints that non-invasive screening might help identify some embryos less likely to result in very early loss, even though it didn't translate into more ongoing pregnancies or live births overall. The authors frame this as an observed association within their trial data rather than proof that the testing method directly prevents miscarriage.

The study found no meaningful differences in maternal or newborn health outcomes between the two approaches, and no serious adverse events were reported in either arm.

How to read these results

The researchers frame their conclusion cautiously: there wasn't enough evidence in this trial to establish that niPGT-A improves the chances of an ongoing pregnancy compared with standard morphology-based embryo selection. For the specific population studied here — women with a relatively good prognosis who already had multiple blastocysts to choose from — the data don't support making this technology a routine part of care.

That doesn't close the book on the approach. Preimplantation genetic testing methods continue to evolve, and outcomes might differ in other patient populations, with refined lab techniques, or with longer-term follow-up. The early miscarriage finding seems worth further scrutiny in future research, since it suggests the technology may be picking up on something biologically meaningful even if it doesn't shift the odds of a live birth in this trial.

For anyone considering advanced fertility technologies like niPGT-A, this study is a useful data point, but it's not a substitute for a conversation with a fertility specialist who can weigh individual circumstances, clinic-specific experience, and the latest evidence. Decisions about embryo selection methods should be made with a treating physician who understands the full clinical picture, not from a single study summary.

Source: Nature Communications, DOI: 10.1038/s41467-026-77628-4, based on a multicenter randomized controlled trial led by Huang, Li, Zeng, Hu, Cai, Chen, and colleagues.